GlassScriptPhysician profile
Jeffrey William Berg
NPI 1376506022
$3,206.35
in general payments reported to CMS, 2019-2025
23 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $596 · 2021: $615 · 2022: $453 · 2023: $244 · 2024: $504 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $737.91 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.60 | 2019-2025 | Relistor |
| Abbvie INC. | $347.50 | 2021-2022 | |
| Boston Scientific Corporation | $272.15 | 2020-2025 | Intracept |
| Pfizer INC. | $265.20 | 2019-2021 | |
| Grt US Holding, INC. | $230.42 | 2020-2022 | |
| Allergan, INC. | $146.62 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $142.26 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $89.92 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $74.24 | 2019-2020 | |
| Horizon Therapeutics Plc | $59.17 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $57.46 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.86 | 2022 | |
| Lilly USA, LLC | $45.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $35.29 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28.43 | 2019 | |
| Amgen INC. | $22.21 | 2022 | |
| Si-Bone, INC. | $21.25 | 2019 | |
| Quidel Corporation | $17.66 | 2022 | |
| Hikma Pharmaceuticals USA | $16.81 | 2022 | |
| Bioventus LLC | $14.52 | 2021 | |
| Assertio Therapeutics, INC. | $14.19 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.